Shift Bioscience, a biotechnology company developing cell rejuvenation therapeutics using its proprietary virtual cell platform, has announced the appointments of Lord David Prior as Chair of the Board and Sir Tony Kouzarides as Scientific Advisor. Both leaders bring extensive experience in healthcare, science, and policy, and will support Shift’s long-term mission to address age-driven diseases by reversing cellular aging.

As Chair of the Board, Lord Prior will guide the company’s strategic direction, with a focus on accelerating its therapeutic pipeline and forging partnerships with the pharmaceutical industry. He will also leverage his deep network across healthcare and government to support investment and business development initiatives. Lord Prior’s career spans law, finance, and public service, including roles as Chair of NHS England, the Care Quality Commission, and Parliamentary Under-Secretary in both the Department of Health and the Department for Business, Energy and Industrial Strategy. He is a vocal proponent of shifting from reactive "sick-care" to proactive, preventative healthcare.

Sir Tony Kouzarides, a leading cancer biologist and pioneer in the Cambridge life sciences ecosystem, will serve as Scientific Advisor. He will play a key role in shaping Shift’s scientific strategy, identifying research opportunities, and elevating the company’s profile in the field of rejuvenation therapeutics. Kouzarides is a professor at the University of Cambridge, co-founder of the Milner Therapeutics Institute and Abcam, and has held leadership roles in several biotech ventures, including STORM Therapeutics and Vellos.

Dr. Daniel Ives, CEO of Shift Bioscience, expressed enthusiasm for the new appointments:
“We are thrilled to welcome Lord David Prior and Sir Tony Kouzarides to our team. Their exceptional leadership and deep expertise will be instrumental in propelling Shift forward as we pursue our mission to combat age-related diseases by targeting the root causes at the cellular level.”

Commenting on his new role, Lord Prior said:
“Shift’s ability to identify genes that reverse or slow aging using advanced machine learning represents a significant breakthrough. These insights have the potential to transform healthcare into a more predictive and preventative model, and I look forward to contributing to this exciting journey.”

Sir Tony Kouzarides added:
Shift is at the forefront of a novel therapeutic paradigm, integrating AI-driven biology with groundbreaking rejuvenation science. I’m delighted to join the company at such a critical stage and look forward to helping steer its scientific and publication strategies.

Source: https://www.shiftbioscience.com/news/shift-bioscience-appoints-lord-david-prior-and-sir-tony-kouzarides